Moxetumomab pasudotox is a recombinant immunotoxin designed for targeted therapy in certain types of cancer, particularly hairy cell leukemia. It is composed of a modified form of the Pseudomonas exotoxin A linked to an anti-CD22 monoclonal antibody. This structure allows it to selectively bind to CD22, a protein commonly expressed on the surface of B-cell malignancies, facilitating the internalization of the toxin into the cancer cells. Once inside, the exotoxin disrupts protein synthesis, leading to cell death. Moxetumomab pasudotox is administered via intravenous infusion and has been evaluated for its efficacy and safety in clinical trials. Common side effects may include infusion-related reactions, fatigue, and hematologic toxicities. Its mechanism of action highlights the potential of immunotoxins in cancer therapy, offering a more targeted approach compared to traditional chemotherapeutics, thereby minimizing damage to healthy tissues. As with any therapeutic agent, its use is accompanied by specific indications and contraindications that must be considered in clinical practice.

Moxetumomab pasudotox

1020748-57-5: Moxetumomab pasudotox is a recombinant immunotoxin designed for targeted therapy in certain types of cancer, particularly hairy cell leukemia. It is composed of a modified form of the Pseudomonas exotoxin A linked to an anti-CD22 monoclonal antibody. This structure allows it to selectively bind to CD22, a protein commonly expressed on the surface of B-cell malignancies, facilitating the internalization of the toxin into the cancer cells. Once inside, the exotoxin disrupts protein synthesis, leading to cell death. Moxetumomab pasudotox is administered via intravenous infusion and has been evaluated for its efficacy and safety in clinical trials. Common side effects may include infusion-related reactions, fatigue, and hematologic toxicities. Its mechanism of action highlights the potential of immunotoxins in cancer therapy, offering a more targeted approach compared to traditional chemotherapeutics, thereby minimizing damage to healthy tissues. As with any therapeutic agent, its use is accompanied by specific indications and contraindications that must be considered in clinical practice.

<p>Moxetumomab pasudotox (CAT 8015), an anti-CD22 immunotoxin for researching hairy cell leukemia.</p>

CAS 1020748-57-5

Moxetumomab pasudotox

Moxetumomab pasudotox

Ref: TM-T76783